Repros Therapeutics — Investor Presentation (September 2015)
26 slides from Repros Therapeutics's investor presentation, Sep 29, 2015
Slide 1: Enclomiphene (EnCyzix): A Mechanistically Consistent Approach to Secondary Hypogonadism
Enclomiphene ( EnCyzix ™) A Mechanistically Consistent Approach to the Treatment of Secondary Hypogonadism
Slide 2: Repros Disclaimer
Repros Disclaimer Any statements made by the Company that are not historical facts contained in these slides (or in any oral accompanying discussion) are forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and are subject to various risks, uncertai
Slide 3: Categorising Gonadal Status by Testosterone and LH in EMAS
Categorising Gonadal Status by Testosterone (T) and LH in the European Male Ageing Study (EMAS) : A General Population Observational Cohort Study Thresholds for abnormal: <Total T 10.5 nmol /L (300 ng/ dL ) and >LH 9.4 U/L (Tajar et al J Clin Endocrinol Metab 2010 95:1810) 0 20 40 60 80 LH (U/L) 0 1
Slide 4: Risk Factors for Secondary Obesity-Related Hypogonadism
CM - 4 Risk Factors Age ( yrs ) BMI ≥ 25 - <30 kg/m 2 BMI ≥ 30 kg/m 2 Smoking ( current) Alcohol ( frequent) Co - morbidity ( ≥ 1) 0 5 10 15 *** *** * Adjusted Relative Risk Ratio Secondary Obesity Related Hypogonadism EMAS Tajar, JCEM 2010 0 5 10 15 *** Hypogonadism of Aging * p<0.05 *** p<0.001 Pr
Slide 5: BMI and Age: Different Effects on Hormones
CM - 5 EMAS Wu, JCEM 2008 BMI and Age: Different Effects on Hormones Increasing BMI is associated with progressively lower testosterone levels, independent of age Increasing age is associated with progressively higher LH levels, independent of BMI Testosterone ( nmol /L) LH (U/L) With obesity, LH do
Slide 6: Secondary Hypogonadism at Baseline
Secondary Hypogonadism at Baseline Age (years) BMI ≥ 25 - <30 kg/m2 BMI ≥ 30 kg/m2 Smoking (current) Alcohol (frequent) Morbidity ( ≥ 1) 0 5 10 15 *** *** * Poor morning erection Sexual thoughts Erectile dysfunction Low vigorous activity Unable to bend Slow walking speed 0 2 4 6 * * Adjusted Relativ
Slide 7: Prevalence of Symptomatic Late Onset Hypogonadism Increases with BMI
CM - 7 Prevalence of Symptomatic Late Onset Hypogonadism (LOH) Increases with BMI Wu et al New Eng J Med 2010 EMAS Wu, N Eng J Med 2010 LOH is defined by the presence of 3 sexual symptoms associated with total testosterone <11.0 nmol /L (315 ng/ dL ) and free testosterone of <220 pmol /L (6.3 pg /mL
Slide 8: Secondary Hypogonadism is Reversible with Weight Loss
CM - 8 n = 2395, *p<0.05, **p<0.01 % Weight loss Weight gain % 0 * ** * * * Camacho et al. European Journal of Endocrinology 2013 Mean (SEM) Secondary Hypogonadism is REVERSIBLE with WEIGHT LOSS Secondary Hypogonadism DEVELOPS with WEIGHT GAIN Testosterone Changes Related Weight Change
Slide 9: Age-Related Hypogonadism
CM - 9 Age - Related Hypogonadism In recent years, use of testosterone therapies has increased markedly among middle - aged and elderly men for a controversial condition that the FDA calls “ age - related hypogonadism , ” also referred to as “ late onset hypogonadism , ” a condition which is typical
Slide 10: Increasing Testosterone Prescription Claims by Age, 2010-2013
CM - 10 Increasing Number of Prescription Claims for Testosterone Products from U.S. Outpatient Retail Pharmacies, Stratified According to Age, 2010 – 2013 Nguyen et al N Eng J Med 2015 9% 3%
Slide 11: Global Prevalence of Obesity in Adults 1980-2013
CM - 11 Global, Regional, and National Prevalence of Obesity in Adults During 1980 - 2013: Global Burden of Disease Study 2013 - Obesity Does not Increase with Age >60 Yr Ng et al, Lancet 2014
Slide 12: What Do We Know About Men Seeking Treatment for Hypogonadism?
CM - 12 So What Do We Know About the Current Group of Men Seeking Treatment for Hypogonadism? The majority are secondary hypogonadal and are fertile Confirmatory diagnosis not practiced in the US No studies conducted by hormone replacement sponsors to assess impact on spermatogenesis “But th
Slide 13: Units of Testosterone and Clomiphene Sold
Units of Testosterone and Clomiphene Sold 0 200 400 600 800 1000 1200 0 5000 10000 15000 20000 25000 30000 35000 40000 45000 Mar Apr May June July Aug Sep Oct Nov Dec Jan Feb Mar Apr May June July Aug Sep Oct Nov Dec Jan Feb Units of Clomiphene Sold (000) Units of Testosterone Sold (000) Monthly Uni
Slide 14: Is There Anything Else to Worry About if I Take T?
CM - 14 “So is there anything else to worry about if I take T?” “I don’t want to have any more kids” You have a reversible disorder if you are willing to make a lifestyle change If you start taking testosterone you may need to take it for the rest of your life Conclusions : Interruption of T
Slide 15: Conclusions: Clinical Implications
CM - 15 Conclusions: Clinical Implications Diagnostic differentiation of secondary from primary hypogonadism is essential – measure T and LH – The commonest form of T deficiency in ‘aging’ men is Secondary Hypogonadism associated with obesity (independent of ageing) due to reversible functional su
Slide 16: Why Not Just Use Clomid?
Why Not Just Use Clomid ? Enclomiphene (Patented) Trans Isomer (Pure Estrogen Antagonist) of Clomiphene Commercial Clomid (60% Trans, 40% Cis) 0 20 40 60 80 100 0.01 1 100 10000 % Concentration ( nM ) Estrogen Receptor Binding Affinity zu en Trough Concentration of Enclomiphene In Serum at Steady St
Slide 17: Clomiphene Isomers Exhibit Different Impact on Urogenital Tract Tissues
Clomiphene Isomers Exhibit Different Impact on Animal Urogenital Tract Tissues 0 5 10 15 20 25 Blood Testis Epididymis Seminal vesicles Kidneys ng Equivalent [ 14 C] clomiphene isomers /Kg Zuc 4 Hr Zuc 24 Hr Enc 4 Hr Enc 24 Hr Single 20 mg/kg radiolabeled dose 90 Day Exposure @ 40 and 4 mg/kg Contro
Slide 18: How Enclomiphene Works
How Enclomiphene Works Enclomiphene blocks estrogen at the level of the H - P axis increasing LH levels which in turn increases endogenous production of T 0 1 2 3 4 5 6 7 Enclomiphene LH Androgel LH Median LH ( mIU /mL) Impact on LH in 16 Wk Study ZA - 304 Baseline End of Study 0 50 100 150 200 250
Slide 19: ZA-304 & ZA-305 Results
ZA - 304 & ZA - 305 Results Enclomiphene Yields Meaningful Reproducible Outcomes Study ZA - 304 (p - values Treatment vs Enclomiphene) ZA - 305 (p - values Treatment vs Enclomiphene) Treatment Enclomiphene Androgel Placebo Enclomiphene Androgel Placebo N 41 43 45 44 42 41 Age (SD) 49.1 (7.4) 47.4 (7
Slide 20: Enclomiphene Exhibits No Negative Effects on Spermatogenesis
Enclomiphene Exhibits No Negative Effects on Spermatogenesis Unlike Exogenous T -70 -60 -50 -40 -30 -20 -10 0 10 20 % Change from Baseline Impact on Sperm Concentration After 16 Wks Treatment ZA - 304 Enclomiphene Androgel Placebo 0 10 20 30 40 50 60 % of Oligospermic Subjects % of Subjects Becoming
Slide 21: Enclomiphene Averages Over 77% of Men in Normal Range
Enclomiphene Averages > 75 % of Men Studied in Normal Range • 10 studies conducted with durations up to 1 year • Table determined as LOCF for morning T Study Subjects Receiving Enclomiphene Study Duration % Morning T in Normal Range (LOCF) ZN - 018 22 2 Wks. 77.3 ZA - 003 97 3 Mo. 63.9 ZA - 203 57 3
Slide 22: Enclomiphene Unique Profile vs Approved Hormone Replacement
Enclomiphene Exhibits Unique Profile with Numerous Advantages vs Approved Hormone Replacement • The Enclomiphene Advantages – Oral – Not controlled substance, cannot be abused – No supernormal levels of T achieved – No transference risk – Restores normal function (no loss of testicular function) – D
Slide 23: Enclomiphene Regulatory Status
Enclomiphene Regulatory Status • NDA accepted by FDA – Treatment of secondary hypogonadism in overweight men – NDA filing requests NCE (New Chemical Entity) status • EMA (European Medicines Agency) notes enclomiphene is eligible for submission for a centralized marketing authorisation application (M
Slide 24: Enclomiphene US Commercial Plan/Schedule
Enclomiphene US Commercial Plan/Schedule • Completed Activities Year - to - Date – NDA filed – Initiated EU filing activities (anticipate central filing 2/16) – Adcom consultancy ( Pharmapprove ) hired and active • Two Mock Panels conducted • Q4 - 15 – Build launch inventory – Award sales contract –
Slide 25: Proellex Status and Plans Going Forward
Proellex Status and Plans Going Forward • Ongoing Phase 2b Proellex studies – Uterine fibroids (vaginal and oral administration studies) • Rapid and maintained reduction in bleeding • Reduction of fibroid bulk • Reduction of bulk associated symptoms – Endometriosis • Rapid reduction in menstrual and
Slide 26: Financial Summary
Financial Summary • Cash and equivalents: (unaudited end of Q2 2015) $32.2 M • Cash used in 2015 (through June 30, 2015) : $14.5 M • Cash runway: H2 2016 • Current shares outstanding: 24.3 M shares – Warrants Outstanding – Series A – 2,502 (purchased in unit deal @ $2.45); Series B – 429,704 @ $2.49
Repros Therapeutics — Investor Presentation (September 2015) on 6ix